Eyegate Pharmaceuticals, Inc.

Description

• We are a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EGP-437, our first product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through our proprietary innovative drug delivery system, the EyeGate® II Delivery System. EGP-437 is being developed under the 505(b)(2) New Drug Application, or NDA, regulatory pathway for drugs submitted for approval to the U.S. Food and Drug Administration, or FDA, which enables an applicant to rely, in part, on the FDAs findings of safety and efficacy for an existing product, or published literature, in support of its NDA.In addition, through our acquisition of Jade in March 2016 (the Jade Acquisition), we are developing products using cross-linked thiolated carboxymethyl hyaluronic acid (CMHA-S), a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing properties when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries. Our first CMHA-S-based product, the EyeGate Ocular Bandage Gel (OBG), is a topically-applied eye drop formulation that is being developed under the 510(k) De Novo path for devices submitted for marketing clearance to the U.S. FDA.
• 

  Headquarters:271 Waverley Oaks Road , Waltham, Massachusetts, United States

  More
• 

  Phone Number: +1 781-788-9043

• 

  Website: https://www.eyegatepharma.com

• 

  Employees:13

• 

  Revenue:$10 - 50M

• 

  Legal Name:Eyegate Pharmaceuticals, Inc.

• Eyegate Pharmaceuticals, Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 423450  |

  Show More